HIV-associated nephropathy (HIVAN) is the leading cause of end-stage renal failure in HIV-1 seropositive patients. The pathologic findings include collapsing focal segmental glomerulosclerosis with proliferation of epithelial cells in Bowman’s space. Anatomically, these cells correspond to podocytes and exhibit a unique phenotype with loss of many differentiation markers including synaptopodin and dysregulation of the cell cycle markers consistent with proliferation. Podocyte dysfunction appears to be a direct result of HIV-1 protein expression, specifically Nef and Vpr as well as specific host factors that have yet to be elucidated. The mechanism by which Nef induces podocyte proliferation and dedifferentiation has been traced to its ability to activate several signaling pathways including Src-Stat3 and ras-raf-MAPK1, 2. Activation of the cAMP/PKA pathway with all-trans-retinoic acid appears to modulate these changes and returns podocytes to a differentiated, nonproliferating phenotype.

Keywords:
HIV-associated nephropathy, Podocyte, Protein expression, Retinoids
1.
USRDS 2005 Annual Data Report: Atlas of End-Stage-Renal-Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005/2006.
2.
Rao TK, Filippone EJ, Nicastri AD, et al: Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669–673.
3.
Rao TK, Friedman EA, Nicastri AD: The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987;316:1062–1068.
4.
Carbone L, D’Agati V, Cheng JT, Appel GB: Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med 1989;87:389–395.
5.
D’Agati V, Suh JI, Carbone L, Cheng JT, Appel G: Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989;35:1358–1370.
6.
Chander P, Soni A, Suri A, Bhagwat R, Yoo J, Treser G: Renal ultrastructural markers in AIDS-associated nephropathy. Am J Pathol 1987;126:513–526.
7.
D’Agati V, Appel GB: HIV infection and the kidney. J Am Soc Nephrol 1997;8:138–152.
8.
Barisoni L, Kriz W, Mundel P, D’Agati V: The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999;10:51–61.
9.
Nagata M, Nakayama K, Terada Y, Hoshi S, Watanabe T: Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 1998;153:1511–1520.
10.
Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P: Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000;58:137–143.
11.
Dijkman HB, Weening JJ, Smeets B, et al: Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells. Kidney Int 2006;70:338–344.
12.
Barisoni L, Bruggeman LA, Mundel P, D’Agati VD, Klotman PE: HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int 2000;58:173–181.
13.
Schwartz EJ, Cara A, Snoeck H, et al: Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 2001;12:1677–1684.
14.
Cohen AH, Sun NC, Shapshak P, Imagawa DT: Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol 1989;2:125–128.
15.
Bruggeman LA, Ross MD, Tanji N, et al: Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000;11:2079–2087.
16.
Winston JA, Bruggeman LA, Ross MD, et al: Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001;344:1979–1984.
17.
Marras D, Bruggeman LA, Gao F, et al: Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002;8:522–526.
18.
Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D’Agati V, Alpers CE: Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000;58:674–683.
19.
Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997;100:84–92.
20.
Zhong J, Zuo Y, Ma J, et al: Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 2005;68:1048–1060.
21.
Abbott KC, Hypolite I, Welch PG, Agodoa LY: Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001;14:377–383.
22.
Laradi A, Mallet A, Beaufils H, Allouache M, Martinez F: HIV-associated nephropathy: outcome and prognosis factors. Groupe d’ Etudes Nephrologiques d’Ile de France. J Am Soc Nephrol 1998;9:2327–2335.
23.
Dickie P, Felser J, Eckhaus M, et al: HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991;185:109–119.
24.
Kopp JB, Klotman ME, Adler SH, et al: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 1992;89:1577–1581.
25.
Gharavi AG, Ahmad T, Wong RD, et al: Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci USA 2004;101:2488–2493.
26.
Kaufman L, Hayashi K, Ross MJ, Ross MD, Klotman PE: Sidekick-1 is upregulated in glomeruli in HIV-associated nephropathy. J Am Soc Nephrol 2004;15:1721–1730.
27.
Ross MD, Bruggeman LA, Hanss B, et al: Podocan, a novel small leucine-rich repeat protein expressed in the sclerotic glomerular lesion of experimental HIV-associated nephropathy. J Biol Chem 2003;278:33248–33255.
28.
Hayashi K, Kaufman L, Ross MD, Klotman PE: Definition of the critical domains required for homophilic targeting of mouse sidekick molecules. FASEB J 2005;19:614–616.
29.
Husain M, Gusella GL, Klotman ME, et al: HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002;13:1806–1815.
30.
Sunamoto M, Husain M, He JC, Schwartz EJ, Klotman PE: Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int 2003;64:1695–1701.
31.
Husain M, D’Agati VD, He JC, Klotman ME, Klotman PE: HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS 2005;19:1975–1980.
32.
Zuo Y, Matsusaka T, Zhong J, et al: HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol 2006;17:2832–2843.
33.
Kestler HW 3rd, Ringler DJ, Mori K, et al: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65:651–662.
34.
Fackler OT, Baur AS: Live and let die: Nef functions beyond HIV replication. Immunity 2002;16:493–497.
35.
Papkalla A, Munch J, Otto C, Kirchhoff F: Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol 2002;76:8455–8459.
36.
Baur AS, Sawai ET, Dazin P, Fantl WJ, Cheng-Mayer C, Peterlin BM: HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1994;1:373–384.
37.
Federico M, Percario Z, Olivetta E, et al: HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 2001;98:2752–2761.
38.
Messmer D, Bromberg J, Devgan G, Jacque JM, Granelli-Piperno A, Pope M: Human immunodeficiency virus type 1 Nef mediates activation of STAT3 in immature dendritic cells. AIDS Res Hum Retrovir 2002;18:1043–1050.
39.
Tobiume M, Fujinaga K, Suzuki S, Komoto S, Mukai T, Ikuta K: Extracellular Nef protein activates signal transduction pathway from Ras to mitogen-activated protein kinase cascades that leads to activation of human immunodeficiency virus from latency. AIDS Res Hum Retrovir 2002;18:461–467.
40.
Martin GS: The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467–475.
41.
He JC, Husain M, Sunamoto M, et al: Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1, 2 pathways. J Clin Invest 2004;114:643–651.
42.
Evans TR, Kaye SB: Retinoids: present role and future potential. Br J Cancer 1999;80:1–8.
43.
Lehrke I, Schaier M, Schade K, et al: Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. Am J Physiol 2002;282:F741–F751.
44.
Wagner J, Dechow C, Morath C, et al: Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000;11:1479–1487.
45.
Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, et al: Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 2003;139:823–831.
46.
Licht JD, Zelent A: Retinoid and growth factor receptor signaling in APL. Blood 2005;105:1381–1382.
47.
He JC, Lu TC, Fleet M, Sunamoto M, Husain M, Fang W, Neves S, Chen Y, Shankland S, Iyengar R, Klotman PE: Retinoic acid inhibits HIV-1 induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007;18:93–102.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.